Who
Lindsay A. Rosenwald
Director
Company insider
Files Form 4 as: Director, Journey Medical; President, CEO & Chairman, Fortress Biotech; Director, Checkpoint Therapeutics; Director, Avenue Therapeutics; Director, Mustang Bio; Co-Chairman and CEO, CB Pharma Acquisition; Director and 10% owner, Cougar Biotechnology; 10% owner, Innovive Pharmaceuticals.
In numbers
- Trades disclosed
- 188
- Buys
- 61
- Sells
- 2
- Bought
- $12.1M
- Sold
- $1.2M
- Companies
- 13
- Companies where not an officer
- 10
- First trade
- 11 Jan 2006
- Last trade
- 25 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 26 Jun 2026 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 18 Mar 2026filed 20 Mar 2026 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Code A | —475,424 at $0.00 | filing |
| 18 Mar 2026filed 20 Mar 2026 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Code A | —475,424 at $0.00 | filing |
| 5 Aug 2025filed 7 Aug 2025 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 25 Jun 2025filed 7 Jul 2025 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —7,173 at $0.00 | filing |
| 30 May 2025filed 30 May 2025 | Checkpoint Therapeutics | SEC FORM 4 Code U | —207,007 | filing |
| 29 May 2025filed 30 May 2025 | Checkpoint Therapeutics | SEC FORM 4 Code A | $65K50,000 at $1.29 | filing |
| 28 May 2025filed 30 May 2025 | Checkpoint Therapeutics | SEC FORM 4 Code A | —12,195 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Code A | —454,153 at $0.00 | filing |
| 13 Dec 2024filed 17 Dec 2024 | Checkpoint Therapeutics | SEC FORM 4 Code A | —12,638 at $0.00 | filing |
| 23 Sep 2024filed 25 Sep 2024 | Avenue Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Sep 2024filed 25 Sep 2024 | FBIO Fortress Biotechoption or derivative · Biotechnology | SEC FORM 4 Code P | $99K763,359 at $0.13 | filing |
| 23 Sep 2024filed 25 Sep 2024 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Bought | $1.4M763,359 at $1.84 | filing |
| 11 Jul 2024filed 15 Jul 2024 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Bought | $37K5,000 at $7.48 | filing |
| 9 Jul 2024filed 11 Jul 2024 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Bought | $37K5,000 at $7.39 | filing |
| 8 Jul 2024filed 10 Jul 2024 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Bought | $37K5,000 at $7.35 | filing |
| 8 Jul 2024filed 10 Jul 2024 | DERM Journey MedicalPharmaceuticals | SEC FORM 4 Code A | —9,728 at $0.00 | filing |
| 28 Jun 2024filed 1 Jul 2024 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Bought | $33K20,000 at $1.64 | filing |
| 16 May 2024filed 20 May 2024 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Bought | $18K10,000 at $1.76 | filing |
News
Journey Medical (NASDAQ:DERM) Downgraded by Wall Street Zen to "Hold"DERM · tickerreport.com · 18 Oct 2026Head to Head Analysis: Fortress Biotech (NASDAQ:FBIO) versus 60 Degrees Pharmaceuticals (NASDAQ:SXTP)FBIO · tickerreport.com · 17 Oct 2026Critical Survey: Fortress Biotech (NASDAQ:FBIO) vs. 60 Degrees Pharmaceuticals (NASDAQ:SXTP)FBIO · tickerreport.com · 11 Oct 2026Contrasting Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM)DERM · themarketsdaily.com · 8 Oct 2026Eli Lilly and Company (NYSE:LLY) and Fortress Biotech (NASDAQ:FBIO) Critical ReviewFBIO · themarketsdaily.com · 7 Oct 2026
0 headlines in the last 90 days name Lindsay A. Rosenwald; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.